Nanoallergen platform for detection of platin drug allergies

Deak, Peter E.; Kim, Baksun; Adnan, Ather; Labella, Marina; Vecillas, Leticia de las; Castells, Mariana; Bilgiçer, Başar

doi:10.1016/j.jaci.2019.01.010

Cited by 16 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the nanostructure concentration that triggered significant degranulation responses in vitro depended on the clinical entity. 60 In another study, the ability of penicilloyl DeAns to stimulate basophils was demonstrated in patients with betalactam allergy (Figure 2D bottom), with basophil response being associated with the size of the nanoconjugates and density of drugs. 61 Therefore, nanostructures in BAT provide the possibility of both increasing the hapten density, because of their multivalent capacity, and presenting the appropriate size for having an optimal sIgE bridging on the basophil surface.…”

Section: Use Of Nanostructures In Detection Of Sige In Cellular Testmentioning

confidence: 91%

“…Nanostructures consisting of liposomes have been used as platforms for drug (oxaliplatin and carboplatin) metabolites displayed in a highly multivalent fashion in the detection of platin-induced allergies. 60 These systems trigger significant degranulation responses from mast cell-like cells (RBL-SX38) primed with serum IgE from patients. Interestingly, the nanostructure concentration that triggered significant degranulation responses in vitro depended on the clinical entity.…”

Section: Use Of Nanostructures In Detection Of Sige In Cellular Testmentioning

confidence: 99%

See 1 more Smart Citation

Role of nanostructures in allergy: Diagnostics, treatments and safety

Mayorga

Pérez‐Inestrosa

Rojo

et al. 2021

Allergy

View full text Add to dashboard Cite

Nanotechnology is science, engineering and technology conducted at the nanoscale, which is about 1-100 nm. It has led to the development of nanomaterials, which behave very differently from materials with larger scales and can have a wide range of applications in biomedicine. The physical and chemical properties of materials of such small compounds depend mainly on the size, shape, composition and functionalization of the system. Nanoparticles, carbon nanotubes, liposomes, polymers, dendrimers and nanogels, among others, can be nanoengineeried for controlling all parameters, including their functionalization with ligands, which provide the desired interaction with the immunological system, that is dendritic cell receptors to activate and/or modulate the response, as well as specific IgE, or effector cell receptors.However, undesired issues related to toxicity and hypersensitivity responses can also happen and would need evaluation. There are wide panels of accessible structures, and controlling their physico-chemical properties would permit obtaining safer and more efficient compounds for clinical applications goals, either in diagnosis or treatment. The application of dendrimeric antigens, nanoallergens and nanoparticles in allergy diagnosis is very promising since it can improve sensitivity by increasing specific IgE binding, mimicking carrier proteins or enhancing signal detection. Additionally, in the case of immunotherapy, glycodendrimers, liposomes, polymers and nanoparticles have shown interest, behaving as platforms of allergenic structures, adjuvants or protectors of allergen from degradation or having a depot capacity. Taken together, the application of nanotechnology to allergy shows promising facts facing important goals related to the improvement of diagnosis as well as specific immunotherapy.

show abstract

Section: Use Of Nanostructures In Detection Of Sige In Cellular Testmentioning

confidence: 91%

Section: Use Of Nanostructures In Detection Of Sige In Cellular Testmentioning

confidence: 99%

Role of nanostructures in allergy: Diagnostics, treatments and safety

Mayorga

Pérez‐Inestrosa

Rojo

et al. 2021

Allergy

View full text Add to dashboard Cite

show abstract

“…The aim would be to improve diagnosis accuracy and to avoid the risks and delays of skin testing. 43 Treating Type I Reactions and Anaphylaxis With Drug Desensitization DD is a robust evidence-based therapeutic procedure that induces a temporary hyporesponsive state by an incremental escalation of suboptimal doses and is drug-specific. DD in vitro models reveal impaired internalization of Ag/IgE-Fc3RI complexes, inhibition of extracellular calcium influx, and the release of mediators (Fig 2).…”

Section: Other In Vitro Biomarkersmentioning

confidence: 99%

Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor–monoclonal antibodies and desensitization

Labella

Castells

2021

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

To review type 1 hypersensitivity reactions and anaphylaxis to checkpoint inhibitor−monoclonal antibodies and its management with drug desensitization. Data Sources: English-language literature on MEDLINE regarding hypersensitivity, anaphylaxis, and checkpoint inhibitor−monoclonal antibodies. Study Selections: References were selected based on relevance, novelty, robustness, and applicability. Results: There are well-known tissue toxicities associated to checkpoint inhibitors, but hypersensitivity reactions and anaphylaxis have been underreported. The presentation of these reactions is based on clinical phenotypes with underlying endotypes identified by specific biomarkers. Drug desensitizations have been successfully applied to checkpoint inhibitor drugs to allow patients with cancer to receive first-line therapies. This review provides current best practices for the recognition and diagnosis of hypersensitivity reactions and anaphylaxis to checkpoint inhibitors and their management using drug desensitization. Conclusion: Hypersensitivity reactions and anaphylaxis have been identified as potential adverse effects induced by checkpoint inhibitor−monoclonal antibodies. Drug desensitization is a safe and effective treatment option for patients who experience hypersensitivity reactions in need of these monoclonal antibodies to improve cancer outcomes.

show abstract

“…This method has several limitations such as rather low cell purity, long analysis time, and nonspecific binding of monocytes that might result in false‐positive signals. Drug metabolite‐presenting liposomes were designed to induce the degranulation of mast cells primed with allergic patients’ sera 60 . A direct correlation between the degranulation induced by liposomal nanoallergens in vitro and the severity of drug hypersensitivity reaction in vivo was reported.…”

Section: Diagnostic Approachesmentioning

confidence: 99%

Advances and novel developments in molecular allergology

Üzülmez

Kalic

Breiteneder

2020

Allergy

View full text Add to dashboard Cite

New technologies are changing the way research is performed in many areas of molecular allergology. 1 Recombinant (r) allergens have influenced the development of allergy diagnosis and allergen-specific immunotherapy (AIT) for over three decades. 2 Although the gold rush of allergen discovery is over, gaps in our knowledge of structures, cross-reactivities, and conformational epitopes are being constantly filled. 2,3

show abstract

Nanoallergen platform for detection of platin drug allergies

Cited by 16 publications

References 16 publications

Role of nanostructures in allergy: Diagnostics, treatments and safety

Role of nanostructures in allergy: Diagnostics, treatments and safety

Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor–monoclonal antibodies and desensitization

Advances and novel developments in molecular allergology

Contact Info

Product

Resources

About